Analysts’ expectations for Resmed Inc (RMD) stock: $250 price target in 12 months

At the time of writing, Resmed Inc [RMD] stock is trading at $213.00, up 3.82%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RMD shares have lost -4.85% over the last week, with a monthly amount drifted -8.36%, and not seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Resmed Inc [NYSE: RMD] stock has seen the most recent analyst activity on March 19, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $280. On January 16, 2025, Goldman initiated with a Buy rating. Piper Sandler started tracking the stock assigning a Neutral rating and suggested a price target of $252 on January 10, 2025. Stifel initiated its recommendation with a Hold and recommended $250 as its price target on December 13, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on September 24, 2024, and assigned it a price target of $280. In a note dated September 18, 2024, Wolfe Research downgraded an Underperform rating on this stock but restated the target price of $180.

For the past year, the stock price of Resmed Inc fluctuated between $172.19 and $263.05. Currently, Wall Street analysts expect the stock to reach $250 within the next 12 months. Resmed Inc [NYSE: RMD] shares were valued at $213.00 at the most recent close of the market. An investor can expect a potential return of 17.37% based on the average RMD price forecast.

Analyzing the RMD fundamentals

According to Resmed Inc [NYSE:RMD], the company’s sales were 4.93B for trailing twelve months, which represents an 10.26% jump. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at 0.32%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.25%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.25 and Total Capital is 0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.16.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 202.32 points at the first support level, and at 191.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 221.27, and for the 2nd resistance point, it is at 229.55.

Ratios To Look Out For

It is important to note that Resmed Inc [NYSE:RMD] has a current ratio of 3.33. Also, the Quick Ratio is 2.29, while the Cash Ratio stands at 0.61. Considering the valuation of this stock, the price to sales ratio is 6.35, the price to book ratio is 5.95 and price to earnings (TTM) ratio is 25.16.

Transactions by insiders

Recent insider trading involved Farrell Michael J., Officer, that happened on Apr 07 ’25 when 8009.0 shares were purchased. Director, FARRELL PETER C completed a deal on Apr 02 ’25 to sell 2000.0 shares. Meanwhile, Global General Counsel Rider Michael J sold 64.0 shares on Apr 01 ’25.

Related Posts